5-HT2B receptor antagonists
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 11, 2005
app pub date -
Aug 14, 2003
filing date -
Feb 13, 2002
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to compounds which include compounds of the formula I: 1 or a pharmaceutically acceptable salt thereof, wherein one of R.sup.1 and R.sup.4 is selected from the group consisting of H, and optionally substituted C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-C.sub.1-4 alkyl, and phenyl-C.sub.1-4 alkyl; and the other of R.sup.1 and R.sup.4 is an optionally substituted C.sub.9-14 aryl group; R.sup.2 and R.sup.3 are either: (i) independently selected from H, R, R', SO.sub.2R, C(.dbd.O)R, (CH.sub.2).sub.nNR.sup.5R.sup.6, where n is from 1 to 4 and R.sup.5 and R.sup.6 are independently selected from H and R, where R is optionally substituted C.sub.1-4 alkyl, and R' is optionally substituted phenyl-C.sub.1-4 alkyl, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C.sub.5-7 heterocyclic group. The compounds are useful in the treatment of conditions including conditions which can be alleviated by antagonism of a 5-HT.sub.2B receptor such as GI disorders and congestive heart failure.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully